RSI Chief Medical Officer, Dr. Donald R. Mattison, in collaboration with colleagues from the Institute for Safe Medication Practices and Wake Forest University, evaluated and compared the safety profiles of newer contraceptives using 43,324 adverse event case reports submitted to the Food and Drug Administration (FDA) Adverse Event Reporting System (FAERS), for the two years ending July 2017. The presentation on Saturday, March 10, 2018 in San Diego described the strong safety profiles of the newer contraceptives, as well as issues of concern.
For more details see the presentation poster here.
Posted in RSI News
More RSI News
Dr. Donald R. Mattison co-authors: Adult Utilization of Psychiatric Drugs
Because there is limited information available concerning the use of psychiatric drugs among the US adult population, Drs Moore and Mattison sought to characterize adult…
Read News ItemRSI launches game-changing climate app
RSI launched the Climate Change Hazards Information Portal (CCHIP).
Read News ItemClimate change modelling for the Bow River watershed
Following up on the recommendations put forth by the Expert Management Panel on River Flood Mitigation, the Environmental and Safety Management (ESM) and Water Resources (WS)…
Read News ItemQuarterWatch analyzes MedWatch Reports
This issue of QuarterWatch analyzes MedWatch Reports from the third quarter of 2015. This issue identifies major differences in reports of cancer associated with drugs…
Read News Item